Omar Albanyan

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni et al. · Science Advances · 2023 · 59 citations · Full text

Life Sciences, Hematology, Immunology +16

The <scp>CAR‐HEMATOTOX</scp> score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory <scp>MCL</scp>

Kai Rejeski, Yucai Wang, Omar Albanyan et al. · American Journal of Hematology · 2023 · 46 citations · Full text

Medicine, Hematology, Oncology +17

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Veit Bücklein, Ariel Perez Perez, Kai Rejeski et al. · HemaSphere · 2023 · 35 citations · Full text

Medicine, Hematology, Oncology +17

High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma

Feras Zaiem, Rada Jerbi, Omar Albanyan et al. · Avicenna Journal of Medicine · 2020 · 17 citations · Full text

Medicine, Oncology, Pathology +17

Grade 3–4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation

Dipenkumar Modi, Omar Albanyan, Seongho Kim et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2021 · 10 citations

Medicine, Hematology, Cell Therapy +14